257 related articles for article (PubMed ID: 24778997)
21. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
[TBL] [Abstract][Full Text] [Related]
22. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
Szer J; Hill A; Weitz IC
Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
[TBL] [Abstract][Full Text] [Related]
23. The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria.
Kulasekararaj AG; Brodsky RA; Nishimura JI; Patriquin CJ; Schrezenmeier H
Ther Adv Hematol; 2022; 13():20406207221091046. PubMed ID: 35663504
[TBL] [Abstract][Full Text] [Related]
24. A Rare Case of Paroxysmal Nocturnal Hemoglobinuria With Bilateral Renal Vein Thrombosis.
Lodhi OUH; Sohail S; Hassan D
Cureus; 2020 Jun; 12(6):e8806. PubMed ID: 32724752
[TBL] [Abstract][Full Text] [Related]
25. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
Heo YA
Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
[TBL] [Abstract][Full Text] [Related]
26. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
Röth A; Dührsen U
Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
[TBL] [Abstract][Full Text] [Related]
27. Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria.
DeZern AE; Uknis M; Yuan X; Mukhina GL; Varela J; Saye J; Pu J; Brodsky RA
Exp Hematol; 2014 Oct; 42(10):857-61.e1. PubMed ID: 25034232
[TBL] [Abstract][Full Text] [Related]
28. Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis.
Gullipalli D; Zhang F; Sato S; Ueda Y; Kimura Y; Golla M; Miwa T; Wang J; Song WC
J Immunol; 2018 Aug; 201(3):1021-1029. PubMed ID: 29898960
[TBL] [Abstract][Full Text] [Related]
29. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
[TBL] [Abstract][Full Text] [Related]
30. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria.
Luzzatto L
F1000Res; 2016; 5():. PubMed ID: 26962442
[TBL] [Abstract][Full Text] [Related]
32. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
33. Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.
Fattizzo B; Versino F; Zaninoni A; Marcello APML; Vercellati C; Artuso S; Barcellini W
Front Immunol; 2022; 13():1060923. PubMed ID: 36532073
[TBL] [Abstract][Full Text] [Related]
34. Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations.
Oliver M; Patriquin CJ
J Blood Med; 2023; 14():613-628. PubMed ID: 38084255
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria.
Luzzatto L; Gianfaldoni G
Int J Hematol; 2006 Aug; 84(2):104-12. PubMed ID: 16926130
[TBL] [Abstract][Full Text] [Related]
36. Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia.
Lee M; Narayanan S; McGeer EG; McGeer PL
PLoS One; 2014; 9(1):e87316. PubMed ID: 24489894
[TBL] [Abstract][Full Text] [Related]
37. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria.
Frieri C; Peffault de Latour R; Sicre De Fontbrune F
Expert Opin Emerg Drugs; 2022 Mar; 27(1):33-43. PubMed ID: 35078384
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
Risitano AM; Marotta S
Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
[TBL] [Abstract][Full Text] [Related]
39. The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria.
Kim JS; Lee JW; Kim BK; Lee JH; Chung J
Korean J Hematol; 2010 Dec; 45(4):269-74. PubMed ID: 21253430
[TBL] [Abstract][Full Text] [Related]
40. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
